- 10.6% Revenue Growth Over Third Quarter 2008 - 16.0% Increase in
Adjusted EBITDA Over Third Quarter 2008 NASHVILLE, Tenn., Nov. 10
/PRNewswire-FirstCall/ -- Emdeon (NYSE:EM), a leading provider of
healthcare revenue and payment cycle management solutions, today
announced financial results for the third quarter of 2009. Third
quarter revenue was $235.5 million, an increase of 10.6%, compared
to $212.8 million for the same period in the prior year. GAAP
operating income for the third quarter of 2009 was $18.0 million
compared to $23.1 million for the same period last year. Excluding
equity compensation expense of $12.6 million for the third quarter
of 2009, primarily related to Emdeon's August 2009 public offering,
and $0.7 million for the third quarter of 2008, operating income
for the third quarter of 2009 would have been $30.6 million
compared to $23.8 million for the prior year period. Third quarter
Adjusted EBITDA grew 16.0%, to $60.2 million, or 25.6% of revenue,
from Adjusted EBITDA of $51.9 million, or 24.4% of revenue, in the
comparable period last year. GAAP net income (loss) per diluted
share for the third quarter of 2009 was $(0.09) as compared to
$(0.02) in the same period last year, primarily as a result of the
equity compensation expense associated with the public offering and
income tax expense primarily related to Emdeon's capital structure
and valuation allowances reflected in the current year period.
Adjusted Net Income per fully diluted share for the third quarter
of 2009 was $0.21 compared to $0.17 for the same period last year
using pro forma adjusted fully diluted shares outstanding. "We are
pleased with Emdeon's financial performance for our initial quarter
as a public company," said George Lazenby, Emdeon's chief executive
officer. "During the period, we continued to execute on our
strategies to expand the breadth and scope of our product and
service offerings, including significant progress on integration
efforts related to our recent acquisitions. We are particularly
encouraged by the positive sales momentum generated in our key
strategic areas of enhanced revenue cycle management, payment
integrity and ePrescribing solutions." At September 30, 2009,
Emdeon's cash and cash equivalents totaled $195 million. Total
long-term debt under Emdeon's credit facilities was $858 million,
before unamortized debt discount of $56 million. "We posted solid
financial results in the third quarter. In addition, the proceeds
from our public offering and our continued strong cash flow from
operations have further strengthened Emdeon's financial position,"
said Bob Newport, Emdeon's chief financial officer. "We continue to
streamline our operations and improve our efficiencies while making
the appropriate investments to enhance our long-term success." A
reconciliation of Emdeon's financial results determined in
accordance with U.S. Generally Accepted Accounting Principles
(GAAP) to certain non-GAAP financial measures has been provided in
the financial statement tables included in this release to
supplement its consolidated financial statements presented on a
GAAP basis. An explanation of these non-GAAP measures is also
included below under the heading "Explanation of Non-GAAP Financial
Measures." Financial Outlook Emdeon currently anticipates its
annual revenue, Adjusted EBITDA and Adjusted Net Income per fully
diluted share for 2009 to be as follows: -- 2009 revenue to be
between $915 to $925 million -- 2009 Adjusted EBITDA to be between
$234 to $239 million -- 2009 Adjusted Net Income per fully diluted
share to be between $0.80 to $0.86 Notice of Conference Call and
Webcast Emdeon will conduct a conference call/webcast for investors
and institutional analysts on Tuesday, November 10, 2009 at 5:00 pm
Eastern Time/4:00 pm Central Time to discuss Emdeon's financial
results. To access Emdeon's live conference call and webcast, dial
800-561-2601 (617-614-3518 for international calls) using
conference code 12408553 or visit the Investors section of Emdeon's
website: http://www.emdeon.com/. Please go to the website at least
15 minutes prior to the event to register, download and install any
necessary audio/video software to access the webcast. For those
unable to listen to the live broadcast, conference call replay will
be available for one week following the conference call by calling
888-286-8010 (617-801-6888 for international calls) using
conference code 32630077. A webcast replay will also be archived on
Emdeon's website for at least 30 days following the conference
call. About Emdeon Emdeon (NYSE:EM) is a leading provider of
revenue and payment cycle management solutions, connecting payers,
providers and patients in the U.S. healthcare system. Emdeon's
product and service offerings integrate and automate key business
and administrative functions of its payer and provider customers
throughout the patient encounter. Through the use of Emdeon's
comprehensive suite of products and services, which are designed to
easily integrate with existing technology infrastructures,
customers are able to improve efficiency, reduce costs, increase
cash flow and more efficiently manage the complex revenue and
payment cycle process. For more information, visit
http://www.emdeon.com/. Forward-Looking Statements Statements made
in this press release that express Emdeon's or management's
intentions, plans, beliefs, expectations or predictions of future
events are forward-looking statements, which Emdeon intends to be
covered by the safe harbor provisions for forward-looking
statements contained in the Private Securities Litigation Reform
Act of 1995. These statements often include words such as "may,"
"will," "should," "believe," "expect," "anticipate," "intend,"
"plan," "estimate" or similar expressions. Forward-looking
statements may include information concerning Emdeon's possible or
assumed future results of operations, including descriptions of
Emdeon's revenues, profitability, outlook and overall business
strategy. You should not place undue reliance on these statements
because they are subject to numerous uncertainties and factors
relating to Emdeon's operations and business environment, all of
which are difficult to predict and many of which are beyond
Emdeon's control. Although Emdeon believes that these
forward-looking statements are based on reasonable assumptions, you
should be aware that many factors could affect Emdeon's actual
financial results or results of operations and could cause actual
results to differ materially from those in the forward-looking
statements, including but not limited to: effects of competition,
including competition from entities that are customers for certain
of Emdeon's products and services; Emdeon's ability to maintain
relationships with its customers and channel partners; Emdeon's
ability to effectively cross-sell its products and services to
existing customers and to develop and successfully deploy new or
updated products and services; pricing pressures on Emdeon's
products and services; the anticipated benefits from acquisitions
not being fully realized or not being realized within the expected
time frames; and general economic, business or regulatory
conditions affecting the healthcare information technology and
services industries; as well as the other risks discussed in the
"Risk Factors" and "Management's Discussion and Analysis of
Financial Condition and Results of Operations" sections and
elsewhere in Emdeon's Registration Statement on Form S-1 and the
accompanying Prospectus thereto, as filed with the Securities and
Exchange Commission (the "SEC"), as well as Emdeon's periodic
reports filed with the SEC and other public filings of Emdeon. You
should keep in mind that any forward-looking statement made by
Emdeon herein, or elsewhere, speaks only as of the date on which
made. Emdeon expressly disclaims any intent, obligation or
undertaking to update or revise any forward-looking statements made
herein to reflect any change in Emdeon's expectations with regard
thereto or any change in events, conditions or circumstances on
which any such statements are based. Emdeon Inc. Condensed
Consolidated Statements of Operations (unaudited and amounts in
thousands, except share and per share amounts) For the For the
Three Months Ended Nine Months Ended September 30, September 30,
2008 2009 2008 2009 ---- ---- ---- ---- Revenue $212,808 $235,462
$635,666 $679,888 Costs and expenses: Cost of operations (exclusive
of depreciation and amortization below) 134,451 146,471 405,423
418,079 Development and engineering 7,312 10,045 21,029 24,425
Sales, marketing, general and administrative 22,220 33,823 69,309
85,146 Depreciation and amortization 25,710 26,667 71,979 77,051
Loss on abandonment of leased properties - 482 - 742 --- --- ---
--- Operating income 23,115 17,974 67,926 74,445 Interest income
(328) (27) (931) (81) Interest expense 20,410 17,219 49,899 52,330
------ ------ ------ ------ Income before income tax provision
3,033 782 18,958 22,196 Income tax provision 3,512 9,245 11,202
12,885 ----- ----- ------ ------ Net income (loss) (479) (8,463)
7,756 9,311 Net income (loss) attributable to noncontrolling
interest 766 (1,246) 2,620 2,871 --- ------ ----- ----- Net income
(loss) attributable to Emdeon Inc. $(1,245) $(7,217) $5,136 $6,440
======= ======= ====== ====== Net income (loss) per share Class A
common stock: Basic $(0.02) $(0.09) $0.07 $0.08 ====== ====== =====
===== Diluted $(0.02) $(0.09) $0.07 $0.08 ====== ====== ===== =====
Weighted average common shares outstanding: Basic 77,413,610
84,522,085 73,889,095 79,809,140 ========== ========== ==========
========== Diluted 77,413,610 84,522,085 73,889,095 79,856,588
========== ========== ========== ========== Emdeon Inc. Condensed
Consolidated Balance Sheets (unaudited and amounts in thousands,
except share amounts) Dec. 31, Sept. 30, 2008 2009 ---- ---- Assets
Current assets: Cash and cash equivalents $71,478 $194,989 Accounts
receivable, net of allowance for doubtful accounts of $4,576 and
$4,499 at December 31, 2008 and September 30, 2009, respectively
144,149 152,460 Deferred income tax assets 2,285 6,233 Prepaid
expenses and other current assets 21,137 17,272 ------ ------ Total
current assets 239,049 370,954 Property and equipment, net 136,038
144,324 Goodwill 646,851 703,008 Intangible assets, net 971,001
963,010 Other assets, net 7,340 1,526 ----- ----- Total assets
$2,000,279 $2,182,822 ========== ========== Liabilities and equity
Current liabilities: Accounts payable $805 $5,623 Accrued expenses
79,513 77,808 Deferred revenues 12,056 12,795 Current portion of
long-term debt 17,244 5,139 ------ ----- Total current liabilities
109,618 101,365 Long-term debt, excluding current portion 807,986
796,768 Deferred income tax liabilities 159,811 151,869 Tax
receivable agreement obligation to related parties - 141,745 Other
long-term liabilities 44,711 29,334 Commitments and contingencies
Equity: Preferred stock (par value $0.00001), 25,000,000 shares
authorized and 0 shares issued and outstanding - - Class A common
stock (par value $0.00001), 400,000,000 shares authorized and
77,413,610 and 90,238,893 shares outstanding at December 31, 2008
and September 30, 2009, respectively 1 1 Class B common stock (par
value $0.00001), 52,000,000 shares authorized and 22,586,390 and
24,752,955 shares outstanding at December 31, 2008 and September
30, 2009, respectively - - Additional paid-in capital 670,702
732,836 Accumulated other comprehensive loss (23,195) (15,511)
Retained earnings 24,123 30,563 ------ ------ Emdeon Inc.
stockholders' equity 671,631 747,889 Noncontrolling interest
206,522 213,852 ------- ------- Total equity 878,153 961,741
------- ------- Total liabilities and equity $2,000,279 $2,182,822
========== ========== Emdeon Inc. Condensed Consolidated Statements
of Cash Flows (unaudited and amounts in thousands) For the Nine
Months Ended September 30, -------------- 2008 2009 ---- ----
Operating activities Net income $7,756 $9,311 Adjustments to
reconcile net income to net cash provided by operating activities:
Depreciation and amortization 71,979 77,051 Equity compensation
expense 5,813 21,499 Deferred income tax expense (benefit) 4,925
(1,360) Amortization of debt issuance costs 141 143 Amortization of
debt discount 7,066 8,699 Amortization of discontinued cash flow
hedge from other comprehensive income 7,011 5,968 Change in fair
value of interest rate swap (12,714) - Loss on abandonment of
leased properties - 742 Loss on disposal of fixed assets 72 56
Changes in operating assets and liabilities: Accounts receivable
(16,968) (3,990) Prepaid expenses and other (9,760) 4,911 Accounts
payable (3,392) 3,515 Accrued expenses and other liabilities
(2,507) (6,199) Deferred revenues 2,879 737 ----- --- Net cash
provided by operating activities 62,301 121,083 ------ -------
Investing activities Purchases of property and equipment (13,942)
(30,563) Payments for acquisitions, net of cash acquired (19,090)
(75,871) Purchase of EBS Master LLC (306,260) - -------- --- Net
cash used in investing activities (339,292) (106,434) --------
-------- Financing activities Proceeds from initial public offering
- 148,261 Repurchase of Class A common stock - (1,573) Repurchase
of Units of EBS Master LLC - (5,372) Debt principal payments
(5,662) (21,663) Payments on revolver - (10,201) Payment of loan
costs - (359) Capital contributions from stockholders 307,451 203
Distribution to shareholders (317) (434) ---- ---- Net cash
provided by financing activities 301,472 108,862 ------- -------
Net increase in cash and cash equivalents 24,481 123,511 Cash and
cash equivalents at beginning of period 33,687 71,478 ------ ------
Cash and cash equivalents at end of period $58,168 $194,989 =======
======== Segment Information (unaudited and amounts in thousands)
For the Three Months Ended September 30, 2008 Corporate & Payer
Provider Pharmacy Elimi- Consoli- nations dated Consolidated
Revenue to external customers Claims management $44,066 $- $- $-
$44,066 Payment services 48,699 - - 48,699 Patient statements -
66,279 - - 66,279 Revenue cycle Management - 36,256 - - 36,256
Dental - 7,939 - - 7,939 Pharmacy services - - 9,569 - 9,569
Inter-segment revenue 77 512 - (589) - Total revenue 92,842 110,986
9,569 (589) 212,808 Costs and expenses: Cost of operations 60,528
72,546 1,816 (439) 134,451 Development and engineering 2,655 3,608
1,049 - 7,312 Sales, marketing, general and administrative 6,004
7,136 1,002 8,078 22,220 Loss on abandonment - - - - - Segment
contribution (1) $23,655 $27,696 $5,702 $(8,228) 48,825
Depreciation and amortization 25,710 Interest income (328) Interest
expense 20,410 Income before income tax provision $3,033 For the
Three Months Ended September 30, 2009 Corporate & Payer
Provider Pharmacy Elimi- Consoli- nations dated Revenue to external
customers Claims management $46,072 $- $- $- $46,072 Payment
services 53,345 - - - 53,345 Patient statements - 69,840 - - 69,840
Revenue cycle management - 39,041 - - 39,041 Dental - 7,978 - -
7,978 Pharmacy services - - 19,186 - 19,186 Inter-segment revenue
297 416 - (713) - Total revenue 99,714 117,275 19,186 (713) 235,462
Costs and expenses: Cost of operations 65,805 75,070 6,158 (562)
146,471 Development and engineering 3,847 4,297 1,901 - 10,045
Sales, marketing, general and administrative 8,037 9,038 3,413
13,335 33,823 Loss on abandonment - - - 482 482 Segment
contribution (1) $22,025 $28,870 $7,714 $(13,968) 44,641
Depreciation and amortization 26,667 Interest income (27) Interest
expense 17,219 Income before income tax provision $782 For the Nine
Months Ended September 30, 2008 Corporate & Payer Provider
Pharmacy Elimi- Consoli- nations dated Consolidated Revenue to
external customers Claims management $134,621 $- $- $- $134,621
Payment services 142,522 - - 142,522 Patient statements - 198,500 -
- 198,500 Revenue cycle management - 106,894 - - 106,894 Dental -
23,938 - - 23,938 Pharmacy services - - 29,191 - 29,191
Inter-segment revenue 298 1,647 - (1,945) - Total revenue 277,441
330,979 29,191 (1,945) 635,666 Costs and expenses: Cost of
operations 182,838 218,311 5,687 (1,413) 405,423 Development and
engineering 7,453 10,472 3,104 - 21,029 Sales, marketing, general
and administrative 18,727 22,888 2,896 24,798 69,309 Loss on
abandonment - - - - - Segment contribution (1) $68,423 $79,308
$17,504 $(25,330) 139,905 Depreciation and amortization 71,979
Interest income (931) Interest expense 49,899 Income before income
tax provision $18,958 For the Nine Months Ended September 30, 2009
Corporate & Payer Provider Pharmacy Elimi- Consoli- nations
dated Revenue to external customers Claims management $137,440 $-
$- $- $137,440 Payment services 156,433 - - - 156,433 Patient
statements - 207,304 - - 207,304 Revenue cycle management - 114,825
- - 114,825 Dental - 23,690 - - 23,690 Pharmacy services - - 40,196
- 40,196 Inter-segment revenue 434 1,388 - (1,822) - Total revenue
294,307 347,207 40,196 (1,822) 679,888 Costs and expenses: Cost of
operations 188,094 221,464 9,947 (1,426) 418,079 Development and
engineering 9,172 11,283 3,970 - 24,425 Sales, marketing, general
and administrative 20,461 24,335 5,439 34,911 85,146 Loss on
abandonment - - - 742 742 Segment contribution (1) $76,580 $90,125
$20,840 $(36,049) 151,496 Depreciation and amortization 77,051
Interest income (81) Interest expense 52,330 Income before income
tax provision $22,196 (1) Segment contribution has been reduced by
equity-based compensation expense of $749, $12,554, $5,813, and
$21,499 for the three months ended September 30, 2008 and September
30, 2009 and for the nine months ended September 30, 2008 and
September 30, 2009, respectively. Segment contribution without such
equity-based compensation expense would have been $49,574, $57,195,
$145,718 and $172,995 for the three months ended September 30, 2008
and September 30, 2009 and for the nine months ended September 30,
2008 and September 30, 2009, respectively. Explanation of Non-GAAP
Financial Measures Emdeon's management team believes that in order
to properly understand Emdeon's short-term and long-term financial
trends, investors may wish to consider the impact of certain
non-cash or non-operating items, when used as a supplement to
financial performance measures prepared in accordance with U.S.
Generally Accepted Accounting Principles (GAAP). These items result
from facts and circumstances that vary in frequency and/or impact
continuing operations. In addition, management uses results of
operations before such items to evaluate the operational
performance of Emdeon as a basis for strategic planning and, in the
case of Adjusted EBITDA, as a performance evaluation metric in
determining achievement of certain executive incentive compensation
programs, as well as for incentive compensation plans for employees
generally. Investors should consider these non-GAAP measures in
addition to, and not as a substitute for, financial performance
measures prepared in accordance with GAAP. In addition to the
description provided below, reconciliations of GAAP to non-GAAP
results are provided in the financial statement tables included in
this release. In this release, Emdeon defines Adjusted EBITDA as
EBITDA (which is defined as net income (loss) before net interest
expense, income tax provision (benefit) and depreciation and
amortization), plus certain other non-cash or non-operating items
(collectively, "EBITDA Adjustments"). In this release, Emdeon
defines Adjusted Net Income as the sum of (i) GAAP net income
(loss), (ii) EBITDA Adjustments, (iii) non-cash interest expense
and (iv) depreciation and amortization expense resulting from
adjustments of assets to fair value in connection with acquisition
accounting, less income taxes computed based on a normalized income
tax rate which removes the income tax impact arising from Emdeon's
structure. Emdeon defines Adjusted Net Income per fully diluted
share as the quotient of Adjusted Net Income and weighted average
shares outstanding, assuming all potentially dilutive securities
are fully outstanding shares from their date of grant or issuance.
To properly and prudently evaluate Emdeon's business, Emdeon
encourages investors to review the GAAP financial information
included in this release, and not rely on any single financial
measure to evaluate Emdeon's business. Emdeon also strongly
encourages investors to review the reconciliation of GAAP net
income (loss) and GAAP net income (loss) per diluted share to the
applicable non-GAAP measures of Adjusted EBITDA, Adjusted Net
Income and Adjusted Net Income per fully diluted share. These
non-GAAP measures, as Emdeon defines them, may not be similar to
non-GAAP measures used by other companies. Management uses Adjusted
EBITDA and Adjusted Net Income per fully diluted share to
facilitate a comparison of Emdeon's operating performance on a
consistent basis from period to period that, when viewed in
combination with Emdeon's GAAP results, management believes
provides a more complete understanding of factors and trends
affecting Emdeon's business than GAAP measures alone. Management
believes these non-GAAP measures assist Emdeon's board of
directors, management, lenders and investors in comparing Emdeon's
operating performance on a consistent basis because they remove
where applicable, the impact of Emdeon's capital and organizational
structure, asset base, acquisition accounting, non-cash charges and
non-recurring items from Emdeon's operations. Emdeon Inc.
Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA
Unaudited (000s) For the Three Months For the Nine Months Ended
September 30, Ended September 30, 2008 2009 2008 2009 Net income
(loss) $(479) $(8,463) $7,756 $9,311 Interest expense (income), net
20,082 17,192 48,968 52,249 Income tax provision (benefit) 3,512
9,245 11,202 12,885 Operating income 23,115 17,974 - 67,926 74,445
Depreciation and amortization 25,710 26,667 71,979 77,051 EBITDA
48,825 44,641 139,905 151,496 Equity-based compensation 749 12,554
5,813 21,499 Purchase accounting adjustments 1,278 311 4,745 1,189
IPO-related transaction costs 300 1,263 300 1,513 Facilities
consolidation costs 758 955 774 1,215 Acquisition related costs -
476 95 772 EBITDA Adjustments 3,085 15,559 11,727 26,188 Adjusted
EBITDA $51,910 $60,200 $151,632 $177,684 Emdeon Inc. Reconciliation
of GAAP Net Income (Loss) to Adjusted Net Income Unaudited (000s)
---------------- For the Three Months For the Nine Months Ended
September 30, Ended September 30, 2008 2009 2008 2009 ---- ----
---- ---- Net income (loss) $(479) $(8,463) $7,756 $9,311 EBITDA
Adjustments 3,085 15,559 11,727 26,188 Non-cash interest expense
4,638 5,073 1,793 14,810 Depreciation and amortization resulting
from acquisition method adjustments 18,580 19,454 51,960 56,986
Adjustment to normalize income tax provision (benefit) (8,076)
(6,898) (22,151) (34,586) ------ ------ ------- ------- Adjusted
Net Income $17,748 $24,725 $51,085 $72,709 ======= ======= =======
======= Emdeon Inc. Reconciliation of Diluted Net Income (Loss) Per
Diluted Share of Class A Common Stock to Adjusted Net Income Per
Fully Diluted Share(1) Unaudited --------- For the Three For the
Nine Months Ended Months Ended September 30, September 30, 2008
2009 2008 2009 ---- ---- ---- ---- Diluted net income (loss) per
share Class A common stock $(0.02) $(0.09) $0.07 $0.08 Impact of
assuming full dilution of all outstanding equity instruments for
the period 0.02 0.02 0.01 0.00 Adjustments on a per share basis:
EBITDA Adjustments 0.03 0.13 0.11 0.24 Non-cash interest expense
0.04 0.04 0.02 0.13 Depreciation and amortization resulting from
acquisition method adjustments 0.18 0.17 0.49 0.52 Adjustment to
normalize income tax provision (benefit) (0.08) (0.06) (0.21)
(0.31) ----- ----- ----- ----- Adjusted Net Income per fully
diluted share $0.17 $0.21 $0.49 $0.66 ===== ===== ===== ===== (1)
The calculation of Adjusted Net Income per fully diluted share
assumes the following equity-based instruments were fully converted
into Class A common stock on their date of issuance: Unaudited
(shares in 000s) -------------------------- For the Three For the
Nine Months Ended Months Ended September 30, September 30, Weighted
average of: 2008 2009 2008 2009 ---- ---- ---- ---- Class A shares
outstanding 77,414 84,522 73,889 79,809 Class B shares outstanding
24,707 25,746 28,126 25,135 Restricted stock units outstanding 919
889 899 933 Options to purchase Class A shares outstanding 2,835
5,023 2,346 3,932 ----- ----- ----- ----- Shares assumed in
Adjusted Net Income per fully diluted share calculation 105,875
116,180 105,260 109,809 ======= ======= ======= ======= DATASOURCE:
Emdeon CONTACT: Investor Relations, Tommy Lewis, +1-615-932-3235,
Web Site: http://www.emdeon.com/
Copyright